Translarna gains renewal of conditional marketing approval by EMA/CHMP
Depressione nel disturbo bipolare, efficace in fase 3 lumateperone
EMA again rejects Kyowa Kirin's MA for istradefylline for 'OFF' episod
Lumateperone effektiv und sicher bei Schizophrenie | Gelbe Liste
Lumateperone: antipsicotico con ridotti effetti avversi metabolici di risperidone – Centro Regionale FarmacoVigilanza Sardegna
Lumateperone: Informazioni sul nuovo antipsicotico - Valerio Rosso
PDF) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. (2019) | Filippo Corponi | 33 Citations
Lumateperone | New Drug Approvals
ViiV nabs EMA marketing authorization for multidrug-resistant HIV
Synthetic Approaches to the New Drugs Approved during 2019 | Journal of Medicinal Chemistry
Albireo files for FDA and EMA approval of odevixibat for PFIC
EMA starts rolling review of COVID-19 vaccine Vidprevtyn
EMA/CHMP recommendations on drug indication extensions
Lumateperone | New Drug Approvals
lumateperone
Lumateperone: Informazioni sul nuovo antipsicotico - Valerio Rosso
Kite's MAA for second CAR-T cell therapy validated by EMA
Diurnal withdraws EMA orphan designation request for Efmody/Chronocort
EMA experts meet with African regulators to discuss opportunities for
PDF) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. (2019) | Filippo Corponi | 33 Citations
Lumateperone | New Drug Approvals
